$IRWD
Ironwood Pharmaceuticals Inc Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914056936 Filed on August 05, 2014

Income Statement

Concept	2014 Q2	2013 Q4	2013 Q2
Revenue	$6.840M	$5.031M	$9.663M
YoY Change	-29.21%	-81.35%	-33.83%
Cost Of Revenue	$10.52M	$500.0K	$3.418M
YoY Change	207.72%	-50.0%
Gross Profit	-$3.678M	$4.500M	$6.245M
YoY Change	-158.9%	-82.69%	-57.23%
Gross Profit Margin	-53.77%	89.45%	64.63%
Selling, General & Admin	$29.30M	$28.70M	$30.87M
YoY Change	-5.09%	-31.01%	53.59%
% of Gross Profit		637.78%	494.32%
Research & Development	$22.14M	$22.50M	$24.09M
YoY Change	-8.1%	-20.49%	-25.27%
% of Gross Profit		500.0%	385.8%
Depreciation & Amortization	$3.100M	$3.100M	$2.800M
YoY Change	10.71%	10.71%	0.0%
% of Gross Profit		68.89%	44.84%
Operating Expenses	$51.44M	$51.30M	$54.96M
YoY Change	-6.41%	-26.61%	5.02%
Operating Profit	-$55.12M	-$46.80M	-$59.88M
YoY Change	-7.95%	6.61%	46.64%
Interest Expense	$5.303M	-$5.200M	$5.318M
YoY Change	-0.28%		40807.69%
% of Operating Profit
Other Income/Expense, Net	-$5.238M	-$5.248M	-$5.269M
YoY Change	-0.59%	-11762.22%	-17096.77%
Pretax Income	-$60.40M	-$52.00M	-$65.10M
YoY Change	-7.22%	18.45%	59.56%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$60.40M	-$52.00M	-$65.10M
YoY Change	-7.22%	18.45%	59.56%
Net Earnings / Revenue	-883.04%	-1033.59%	-673.7%
Basic Earnings Per Share		-$0.43	-$0.57
Diluted Earnings Per Share	-$436.7K	-$0.43	-$0.57
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2013 Q4	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$302.0M	$197.6M	$300.5M
YoY Change	0.5%	17.48%	90.55%
Cash & Equivalents	$95.36M	$75.49M	$219.5M
Short-Term Investments	$206.6M	$122.1M	$81.10M
Other Short-Term Assets	$6.300M	$6.200M	$9.600M
YoY Change	-34.38%	-22.5%	60.0%
Inventory	$12.99M	$22.15M	$20.38M
Prepaid Expenses
Receivables	$4.500M	$513.0K	$5.300M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$325.8M	$229.1M	$335.8M
YoY Change	-2.98%	24.23%	102.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.56M	$37.38M	$35.01M
YoY Change	-4.15%	-0.43%	0.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.597M	$4.311M	$5.091M
YoY Change	-29.35%	1423.32%	-33.88%
Total Long-Term Assets	$45.30M	$49.83M	$48.25M
YoY Change	-6.11%	9.6%	13.27%
TOTAL ASSETS
Total Short-Term Assets	$325.8M	$229.1M	$335.8M
Total Long-Term Assets	$45.30M	$49.83M	$48.25M
Total Assets	$371.1M	$279.0M	$384.0M
YoY Change	-3.38%	21.34%	84.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.393M	$10.14M	$6.569M
YoY Change	-48.35%	-28.68%	-38.03%
Accrued Expenses	$19.05M	$18.44M	$17.12M
YoY Change	11.24%	-12.91%	-14.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.700M	$1.100M	$200.0K
YoY Change	3750.0%	266.67%	-33.33%
Total Short-Term Liabilities	$41.63M	$41.04M	$43.97M
YoY Change	-5.32%	-25.3%	-10.46%
LONG-TERM LIABILITIES
Long-Term Debt	$171.3M	$177.8M	$174.8M
YoY Change	-2.0%	59166.67%	43600.0%
Other Long-Term Liabilities	$16.30M	$1.653M	$1.653M
YoY Change	886.09%	66.63%	-94.56%
Total Long-Term Liabilities	$187.6M	$1.653M	$1.653M
YoY Change	11249.06%	66.63%	-94.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.63M	$41.04M	$43.97M
Total Long-Term Liabilities	$187.6M	$1.653M	$1.653M
Total Liabilities	$229.2M	$42.69M	$45.62M
YoY Change	402.42%	-23.67%	-42.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$887.8M	-$777.8M	-$664.1M
YoY Change	33.69%	54.02%
Common Stock	$1.030B	$815.9M	$803.4M
YoY Change	28.15%	25.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$141.8M	$38.23M	$139.4M
YoY Change
Total Liabilities & Shareholders Equity	$371.1M	$279.0M	$384.0M
YoY Change	-3.38%	21.34%	84.01%

Cashflow Statement

Concept	2014 Q2	2013 Q4	2013 Q2
OPERATING ACTIVITIES
Net Income	-$60.40M	-$52.00M	-$65.10M
YoY Change	-7.22%	18.45%	59.56%
Depreciation, Depletion And Amortization	$3.100M	$3.100M	$2.800M
YoY Change	10.71%	10.71%	0.0%
Cash From Operating Activities	-$36.20M	-$42.10M	-$80.10M
YoY Change	-54.81%	87.95%	85.85%
INVESTING ACTIVITIES
Capital Expenditures	-$700.0K	-$3.700M	-$2.000M
YoY Change	-65.0%	8.82%	-16.67%
Acquisitions
YoY Change
Other Investing Activities	-$79.80M	-$24.30M	$55.20M
YoY Change	-244.57%	-168.07%	-18500.0%
Cash From Investing Activities	-$80.50M	-$28.00M	$53.20M
YoY Change	-251.32%	-186.96%	-2000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.000M	1.200M	141.1M
YoY Change	-95.04%	9.09%	10753.85%
NET CHANGE
Cash From Operating Activities	-36.20M	-42.10M	-80.10M
Cash From Investing Activities	-80.50M	-28.00M	53.20M
Cash From Financing Activities	7.000M	1.200M	141.1M
Net Change In Cash	-109.7M	-68.90M	114.2M
YoY Change	-196.06%	-732.11%	-356.05%
FREE CASH FLOW
Cash From Operating Activities	-$36.20M	-$42.10M	-$80.10M
Capital Expenditures	-$700.0K	-$3.700M	-$2.000M
Free Cash Flow	-$35.50M	-$38.40M	-$78.10M
YoY Change	-54.55%	102.11%	91.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></i></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, available-for-sale securities, inventory valuation and related reserves, impairment of long-lived assets, balance sheet classification of notes payable, income taxes including the valuation allowance for deferred tax assets, research and development expense, contingencies and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</font></p> </div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21016000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20515000	shares
	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS INC
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	122110000	USD
CY2014Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	206618000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	6000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	18000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	4000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	15000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	122112000	USD
CY2014Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	206621000	USD
	irwd	Available For Sale Securities Debt Maturity Period Range High AvailableForSaleSecuritiesDebtMaturityPeriodRangeHigh	P1Y
CY2013Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	12	item
CY2014Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	26	item
CY2013Q4	irwd	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths	0	item
CY2014Q2	irwd	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths	0	item
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	38700000	USD
CY2014Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	85500000	USD
CY2014Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
CY2013Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	22145000	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	12989000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79065000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80828000	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47268000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41689000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33560000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37376000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13784000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	531000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	856000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3267000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18438000	USD
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12488000	USD
CY2014Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	373000	USD
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	706000	USD
CY2014Q2	us-gaap	Interest Payable Current InterestPayableCurrent	856000	USD
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4625000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19048000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	11416000	USD
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	174672000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1653000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6012000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4817000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12086000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10092000	USD
CY2014Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.10	pure
	us-gaap	Severance Costs1 SeveranceCosts1	4334000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	3367000	USD
	us-gaap	Restructuring Charges RestructuringCharges	-551000	USD
CY2014Q2	us-gaap	Restructuring Reserve RestructuringReserve	373000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75490000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	122112000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	513000	USD
CY2013Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	2700000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6168000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	229128000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	8147000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4311000	USD
CY2013Q4	us-gaap	Assets Assets	278962000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10139000	USD
CY2013Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	48000	USD
CY2013Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3412000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1139000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	2790000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5074000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41040000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	3134000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8822000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	371064000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Assets Assets	371064000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Notes Payable Current NotesPayableCurrent	6577000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	41626000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	815930000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-777828000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	38225000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	278962000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	141831000	USD
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Revenues Revenues	9663000	USD
	us-gaap	Revenues Revenues	12918000	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	3418000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4649000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24093000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56846000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30870000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64244000	USD
CY2013Q2	irwd	Collaboration Expense CollaborationExpense	11162000	USD
	irwd	Collaboration Expense CollaborationExpense	35892000	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	69543000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	161631000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-59880000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-148713000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	5318000	USD
	us-gaap	Interest Expense InterestExpense	10439000	USD
CY2013Q2	us-gaap	Investment Income Net InvestmentIncomeNet	49000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	101000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5269000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10338000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65149000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-159051000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	113441000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	110772000	shares
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-60357000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-109983000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-55119000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	61959000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	120951000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-99506000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5238000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10477000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-6000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-13000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65162000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-159057000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	15000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60342000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-109982000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5577000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10092000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-887000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	937000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3811000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	500000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3447000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10197000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-72000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10098000	USD
	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-718000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2379000	USD
	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	-1348000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	661000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-173323000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	144584000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	94142000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4890000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55332000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137766000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	175000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7717000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6515000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	148000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	311416000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	82761000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	19867000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200968000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-94104000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86997000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95357000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136700000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	219461000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2014Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1104000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3597000	USD
CY2014Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	206621000	USD
CY2014Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	4455000	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6338000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	325760000	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	8147000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3393000	USD
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5000	USD
CY2014Q2	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2235000	USD
CY2014Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	2817000	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6447000	USD
CY2014Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	3158000	USD
CY2014Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7431000	USD
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8879000	USD
CY2014Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	168139000	USD
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1029501000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-887811000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3000	USD
CY2014Q2	us-gaap	Revenues Revenues	6840000	USD
	us-gaap	Revenues Revenues	21445000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	10518000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22142000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29299000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	12442000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49286000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	59223000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	5303000	USD
	us-gaap	Interest Expense InterestExpense	10586000	USD
CY2014Q2	us-gaap	Investment Income Net InvestmentIncomeNet	65000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	109000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.82
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	138315000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134053000	shares
CY2014Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	15000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6211000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12086000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-466000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	788000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1242000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	84000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-272000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	116000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7691000	USD
	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-1177000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1164000	USD
	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	-1364000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	206943000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	121969000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2023000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	190428000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11064000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	524000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	8894000	USD
CY2014Q2	us-gaap	Inventory Write Down InventoryWriteDown	8900000	USD
	irwd	Restructuring Adjustment Amount RestructuringAdjustmentAmount	43000	USD
CY2013Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD

Files In Submission

Name	View Source	Status
0001104659-14-056936-index-headers.html	Edgar Link	pending
0001104659-14-056936-index.html	Edgar Link	pending
0001104659-14-056936.txt	Edgar Link	pending
0001104659-14-056936-xbrl.zip	Edgar Link	pending
a14-13913_110q.htm	Edgar Link	pending
a14-13913_1ex31d1.htm	Edgar Link	pending
a14-13913_1ex31d2.htm	Edgar Link	pending
a14-13913_1ex32d1.htm	Edgar Link	pending
a14-13913_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
irwd-20140630.xml	Edgar Link	completed
irwd-20140630.xsd	Edgar Link	pending
irwd-20140630_cal.xml	Edgar Link	unprocessable
irwd-20140630_def.xml	Edgar Link	unprocessable
irwd-20140630_lab.xml	Edgar Link	unprocessable
irwd-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
Ironwood Pharmaceuticals Inc Stock $irwd

2014 Q2 Form 10-Q Financial Statement

#000110465914056936 Filed on August 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD Ironwood Pharmaceuticals Inc Stock $irwd

2014 Q2 Form 10-Q Financial Statement

#000110465914056936 Filed on August 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
Ironwood Pharmaceuticals Inc Stock $irwd